Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs DAPT in ACS with Coronary Artery Ectasia (OVER-TIME)
NCT05233124Phase 2Unknown
- Sponsor
- Instituto Nacional de Cardiología Ignacio Chávez
- Start
- Sep 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rivaroxaban in acute coronary syndrome (ACS), Coronary artery ectasia (CAE), sponsored by Instituto Nacional de Cardiología Ignacio Chávez. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
acute coronary syndrome (ACS)Coronary artery ectasia (CAE)
Beyond the preview
Go deeper on NCT05233124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05233124.